DAPK3/ZIPK Antibody #2928
Filter:
- WB
Supporting Data
REACTIVITY | H M R |
SENSITIVITY | Endogenous |
MW (kDa) | 52 |
SOURCE | Rabbit |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
Product Information
Product Usage Information
Application | Dilution |
---|---|
Western Blotting | 1:1000 |
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.
Protocol
Specificity / Sensitivity
DAPK3/ZIPK Antibody detects endogenous levels of total DAPK3/ZIPK protein.
Species Reactivity:
Human, Mouse, Rat
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Monkey
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues at the carboxyl terminus of human DAPK3/ZIPK. Antibodies were purified by protein A and peptide affinity chromatography.
Background
Death-associated protein kinase (DAPK1) is a Ca2+/calmodulin-regulated serine/threonine kinase that participates in a wide range of apoptotic signals including interferon-γ, tumor necrosis factor α, Fas, activated c-Myc, and detachment from the extracellular matrix. In addition to the kinase domain and calmodulin regulatory segment, DAPK1 also has eight ankyrin repeats, a cytoskeleton binding region, and a conserved death domain (1-3). Deletion of the calmodulin-regulatory domain generates a constitutively active mutant kinase. Ectopic expression of wild-type DAPK1 induced cell death in HeLa cells. Conversely, expression of a catalytically inactive mutant protected cells from interferon-γ-induced cell death (4). The catalytic domain of DAPK1 has very high sequence similarity to vertebrate myosin light chain kinase (MLCK) and a RXX(S/T)X motif derived from myosin light chain protein was shown to be phosphorylated in vitro by DAPK1 (5).
The DAPK family consists of several kinases including DAPK, DAPK2/DRP-1 (6), and DAPK3/ZIPK/DLK (7-9) with homology in their catalytic domain. Overexpression of DAPK3/ZIPK, but not a catalytically inactive mutant, can induce apoptosis (7). DAPK3 was also identified as a myosin light chain kinase, demonstrating ability to phosphorylate the regulatory light chain of myosin II in a Ca2+/calmodulin-independent manner (8). In addition to an amino-terminal kinase domain, DAPK3 contains a carboxy-terminal leucine zipper domain that mediates interaction with leucine zipper transcription factors such as ATF4 (7). DAPK3 is predominantly localized to the nucleus and has been found in PML oncogenic domains (PODs) associated with DAXX and PAR-4, and can phosphorylate PAR-4 in vitro (10,11). In addition, DAPK3 can phosphorylate STAT3 at Ser727 to enhance its transcriptional activity (12).
The DAPK family consists of several kinases including DAPK, DAPK2/DRP-1 (6), and DAPK3/ZIPK/DLK (7-9) with homology in their catalytic domain. Overexpression of DAPK3/ZIPK, but not a catalytically inactive mutant, can induce apoptosis (7). DAPK3 was also identified as a myosin light chain kinase, demonstrating ability to phosphorylate the regulatory light chain of myosin II in a Ca2+/calmodulin-independent manner (8). In addition to an amino-terminal kinase domain, DAPK3 contains a carboxy-terminal leucine zipper domain that mediates interaction with leucine zipper transcription factors such as ATF4 (7). DAPK3 is predominantly localized to the nucleus and has been found in PML oncogenic domains (PODs) associated with DAXX and PAR-4, and can phosphorylate PAR-4 in vitro (10,11). In addition, DAPK3 can phosphorylate STAT3 at Ser727 to enhance its transcriptional activity (12).
- Kimchi, A. (1999) Ann Rheum Dis. 58, I14-I19.
- Cohen, O. et al. (1999) J Cell Biol 146, 141-148.
- Deiss, L. P. et al. (1995) Genes Dev 9, 15-30.
- Cohen, O. et al. (1997) EMBO J 16, 998-1008.
- Velentza, A. V. et al. (2001) J Biol Chem 276, 38956-38965.
- Inbal, B. et al. (2000) Mol Cell Biol 20, 1044-54.
- Kawai, T. et al. (1998) Mol Cell Biol 18, 1642-51.
- Murata-Hori, M. et al. (1999) FEBS Lett 451, 81-4.
- Kögel, D. et al. (1998) Oncogene 17, 2645-54.
- Page, G. et al. (1999) Oncogene 18, 7265-73.
- Kawai, T. et al. (2003) Mol Cell Biol 23, 6174-86.
- Sato, N. et al. (2005) Int Immunol 17, 1543-52.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.